AI-generated analysis. Always verify with the original filing.
Elicio Therapeutics, Inc. announced financial results for the year ended December 31, 2025, reporting R&D expense of $24.9 million, G&A expense of $12.8 million, and net loss of $39.5 million. The company provided updates on the Phase 2 AMPLIFY-7P trial, with event-driven primary DFS analysis anticipated in 1H 2026, and cash runway into Q3 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 12, 2026, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended D
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated March 1 2 , 202 6 . 104 Cover Page Interactive Data
| Metric | Value | Basis |
|---|---|---|
| R&D expense | $24.90 | |
| G&A expense | $12.80 | |
| Net loss | $39.50 | |
| Net loss per share | $2.58 |